Lisa A. Jackson, MD, MPH
“Kaiser Permanente Washington gives us nearly unlimited potential to address vaccine effectiveness and safety questions of national and international importance.”
Lisa A. Jackson, MD, MPH
Senior Investigator, Kaiser Permanente Washington Health Research Institute
Physician, Washington Permanente Medical Group, Internal Medicine
Biography
Lisa A. Jackson, MD, MPH, is an internist and infectious disease epidemiologist who has conducted clinical and epidemiologic studies of vaccine safety and efficacy since 1991.
Dr. Jackson is the principal investigator (PI) of KPWHRI’s Vaccine and Treatment Evaluation Unit — one of 10 network sites that the National Institutes of Health (NIH) sponsors. In this role, she leads the phase 1 clinical trial of the COVID-19 vaccine co-developed by Moderna and NIH. Launched in March 2020, this trial was the first in the world to begin testing a COVID-19 vaccine. She is also leading the phase 3 clinical trials of the COVID-19 vaccines developed by Moderna and NIH and by Janssen Pharmaceutical Companies, part of Johnson & Johnson, at KPWHRI.
Additionally, Dr. Jackson serves as KPWHRI’s principal investigator in the Vaccine Safety Datalink Project (VSDP). Sponsored by the Centers for Disease Control and Prevention (CDC), VSDP conducts ongoing research on the safety of licensed vaccines in routine use.
Dr. Jackson has written more than 200 peer-reviewed publications and 14 book chapters. She is a past member of the Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee and the National Vaccine Program Office’s National Vaccine Advisory Committee.
After receiving her medical degree from the University of Virginia School of Medicine, in Charlottesville, Dr. Jackson earned her Master of Public Health (MPH) degree at the University of Washington (UW) School of Public Health. She completed her internal medicine residency training at the UW School of Medicine and served as an epidemic intelligence officer and preventive medicine resident at the CDC.
Research interests and experience
Vaccines & Infectious Diseases
Vaccine safety; COVID-19 vaccine safety and effectiveness; influenza vaccine effectiveness in the elderly; methodologic issues in vaccine effectiveness evaluations; pneumococcal polysaccharide vaccine effectiveness; pneumococcal conjugate vaccine immunogenicity in the elderly; epidemiology of E. coli bacteremia; epidemiology of community-acquired pneumonia
Recent publications
Belongia EA, Kieke BA, Hanson KE, McClure DL, Boyce TG, Daley MF, DeSilva MB, Hurley LP, Irving SA, Jackson LA, Duffy J, McNeil MM, Sundaram ME Retrospective cohort study of mRNA COVID-19 vaccine-associated enhanced disease in the Vaccine Safety Datalink, 2021-23 2026 Dec;22(1):2681305. doi: 10.1080/21645515.2026.2681305. Epub 2026-06-07. PubMed
DeSilva M, Haapala J, Kharbanda EO, Vesco KK, Daley MF, Getahun D, Raisler K, Naleway AL, Jackson LA, Williams JTB, Klein NP, Jacobson KB, Jorgensen S, Dixon BE, Fuller CC, Weintraub ES, Quincer EM, Lipkind HS, Vazquez-Benitez G Association of Respiratory Syncytial Virus Vaccination During Pregnancy With Adverse Obstetric and Neonatal Outcomes 2026 Jun 18 doi: 10.1097/AOG.0000000000006354. Epub 2026-06-18. PubMed
Williamson BD, Cronkite DJ, Yu O, Ramaprasan A, Fuller S, Covey J, Kiniry E, Park D, Winter R, Whitaker J, McLemore MF, Wittayanukorn S, Stojanovic D, Zhao Y, Dutcher S, Carrell DS, Jackson LA, Nelson JC, Smith JC Identifying anaphylaxis using weakly-supervised prediction models and natural language processing 2026 Jun 17 doi: 10.64898/2026.06.09.26355005. Epub 2026-06-17. PubMed
Quincer EM, Vazquez-Benitez G, Weintraub ES, Walton K, Wang L, Vesco KK, Henninger ML, Daley MF, Hambidge SJ, Williams JTB, Donahue JG, Zerbo O, Getahun D, Jackson LA, Fuller CC, Lipkind HS, Naleway AL, McNeil MM, Kharbanda EO Association Between COVID-19 Vaccination During Pregnancy and Safety Among Infants 2026 Jun 12;15(6). doi: 10.1093/jpids/piag036. PubMed
Balkhi MY, Kalyanasundaram A, Arya A, Kifle DW, Mckinnon M, Krishnappa D, Shrivastava H, Siribie M, Aziz A, Jeon H, Yongchaitrakul T, Tadesse BT, Rakotozandrindrainy N, Razafimanantsoa R, Noellie HB, Ouedraogo NI, Diarra A, Gray SA, Coler RN, Lee J, Rakotozandrindrainy R, Sirima SB, Jackson LA, Marks F, Carter D, Siddiqui AA Schistosomiasis vaccine SchistoShield® induces functional immune memory responses in US and African populations 2026 Jun 2 doi: 10.1038/s41541-026-01501-0. Epub 2026-06-02. PubMed
Irving SA, Crane B, Daley MF, Dixon BE, Donahue JG, Fuller CC, Jackson LA, Getahun D, Glenn SC, Hambidge SJ, Jacobson KB, Kharbanda EO, O'Leary ST, Schmidt T, Raisler K, Weinfield NS, Williams JTB, Zerbo O, Naleway AL 2023-2024 COVID-19 vaccination coverage in pregnancy in ten healthcare delivery organizations in the United States 2026 Apr 19;79:128441 doi:10.1016/j.vaccine.2026.128441. doi: 10.1016/j.vaccine.2026.128441. Epub 2026-03-12. PubMed
Heng F, Magaret CA, Rouphael NG, Branche AR, Fong Y, Carpp LN, Yu C, Chen S, Zhang B, Diemert DJ, Falsey AR, Graciaa DS, Baden LR, Frey SE, Whitaker JA, Little SJ, Kamidani S, Walter EB, Novak RM, Rupp R, Jackson LA, Babu TM, Kottkamp AC, Luetkemeyer AF, Immergluck LC, Presti RM, Bäcker M, Winokur PL, Mahgoub SM, Goepfert PA, Fusco DN, Atmar RL, Posavad CM, Mu J, Makowski M, Makhene MK, Nayak SU, Simon V, van Bakel H, Roberts PC, Gilbert PB The neutralizing antibody titer correlate of COVID-19 risk in the COVID-19 variant immunologic landscape (COVAIL) trial was not modified by SARS-CoV-2 amino acid sequence distances 2026 Mar 19;76:128348 doi:10.1016/j.vaccine.2026.128348. doi: 10.1016/j.vaccine.2026.128348. Epub 2026-02-15. PubMed
Lima NS, McCormick L, Li S, Wake CG, Subramanian R, Spangler A, Pinto Y, Catalano W, Henry AR, Laboune F, Teng IT, Lyke KE, Atmar RL, Deming ME, Jackson LA, Branche AR, Rostad CA, Martin JM, Johnston CM, Rupp RE, Kottkamp AC, Brady RC, Backer M, Edupuganti S, , Posavad CM, Roberts PC, Kwong PD, Andrews S, Schramm CA, Douek DC The vaccine platform used for COVID-19 primary immunization shapes the quality of the human B cell response to a vaccine boost 2026 Feb 25;18(838):eaeb9837 doi:10.1126/scitranslmed.aeb9837. doi: 10.1126/scitranslmed.aeb9837. Epub 2026-02-25. PubMed
Jatt LP, Gillespie KM, Van P, Hoffman SL, Jackson LA, Murphy SC, Heath JR, Kublin JG Manuscript title: Cytokines Associated With Moderate and Severe Adverse Events During a Sporozoite Malaria Vaccine Trial with Controlled Human Malaria Infection 2026 Jan 17;233(1):191-196 doi:10.1093/infdis/jiaf435. doi: 10.1093/infdis/jiaf435. Epub 2025-08-14. PubMed
Duncombe CJ, Hergott DEB, Staubus W, Balke-Buijs M, Kublin JG, Duffy PE, Healy SA, Talley A, Jackson L, Sim BKL, Hoffman SL, Sauerwein RW, Roestenberg M, Murphy SC Sex-based differences in Plasmodium infection in the control groups of controlled human malaria infection trials in malaria-naive populations in the USA and the Netherlands: a pooled analysis 2026 Jan 13 doi: 10.1016/j.lanmic.2025.101265. Epub 2026-01-13. PubMed
Research
Researchers begin trial of C. diff vaccine
KPWHRI is inviting Kaiser Permanente Washington members age 65 and older to take part.
News
Vaccine program recruiting volunteers in Seattle area
KPWHRI’s vaccine registry was the first to enroll participants in a clinical trial of a COVID-19 vaccine.
News
Clinical trial will evaluate mpox vaccine for adolescents
The NIH-sponsored trial will help inform decisions about vaccine approval for 12- to 17-year-olds.
Research
New study confirms safety of shingles vaccine
KPWHRI researchers analyzed data from more than 640,000 vaccine doses to understand risk of severe reactions.
Research
‘Fighting back’ against COVID-19: Remembering a historic trial
Lisa Jackson, MD, MPH, Kaiser Permanente Washington senior investigator, recounts the genesis of a groundbreaking vaccine.
